At-Home ECG Devices in 2026: Watches, Handhelds, and What They Can't See

You can record a real ECG at home in 30 seconds. You probably already have, if you wear a smartwatch. Here is the honest summary of the 2026 market. Watches and handheld devices are very good at finding a heart rhythm problem called atrial fibrillation. They are decent at counting your heart rate. And they cannot see most of what a hospital ECG sees. The right device depends on your goal. Screening, tracking a known condition, or checking a symptom.

Here is what each type can do, what the accuracy data says, and where they all stop.

The short answer

• Screening for AFib: any FDA-cleared watch ECG works. The Apple Watch ECG finds AFib about 95 percent of the time in pooled studies.
• Tracking a known rhythm problem: the KardiaMobile 6L. Six leads, near-perfect accuracy for AFib, around $114.
• Symptoms that come and go: none of the consumer devices. You need a prescription patch that records nonstop for up to 14 days.
• None of these diagnose. They record. A doctor reads the trace. A normal home ECG does not prove your heart is healthy.

The four types

Smartwatch single-lead ECG. The Apple Watch ECG app has been FDA-cleared since 2018. It records a one-lead trace in 30 seconds. It works on Series 4 and later. Samsung's Galaxy Watch has a cleared single-lead ECG too, with two catches. It only works with a Samsung Galaxy phone. And the newest models have less independent testing than Apple's. Withings hybrid watches, like the ScanWatch 2, also carry a cleared ECG.

Handheld single-lead. AliveCor's original KardiaMobile has two thumb pads. It costs about $80 to $130, depending on the model. It does the same job as a watch ECG, but with better skin contact. That helps when a watch trace comes back unreadable.

Handheld six-lead. The KardiaMobile 6L adds a third pad on a strap for your left leg. That buys six views of your heart instead of one. It was the first FDA-cleared six-lead home ECG. It records for 30 seconds and can spot a normal rhythm, AFib, a slow heart rate, and a fast heart rate, with no subscription. The list price is $129. It often sells for around $114. A doctor can read much more from six leads than the app reports.

Hybrid and prescription devices. Withings' BeamO was cleared in November 2025. It costs $249.95 and combines a single-lead ECG with a digital stethoscope and a thermometer. Read the fine print: the FDA cleared the ECG recording, and Withings says the BeamO's AFib detection is still waiting for FDA approval. At the prescription end, sticky patches like the iRhythm Zio record nonstop for up to 14 days. They catch the rhythm problems that dodge a 30-second snapshot. Those need a doctor's order. They are the right tool for fainting or palpitations that come and go.

Accuracy, as measured

The six-lead versus one-lead comparison is the most useful number in the table. In the same patients, doctors reading KardiaMobile 6L traces beat both the Apple Watch and Withings one-lead devices, and the difference was large enough to be real, not luck. If you are tracking a known condition instead of screening once, the six leads are worth the money.

What none of them can see

A single lead shows your heart's rhythm from one angle. It cannot detect most heart attacks, poor blood flow, or wiring problems. It cannot tell where a rhythm problem starts. AliveCor makes a portable 12-lead device, the Kardia 12L, that is cleared to flag 39 heart problems, including heart attacks. But doctors direct that device. It is not a buy-it-for-the-medicine-cabinet product.

Two limits apply to every consumer device. First, they are all snapshots or short recordings. A rhythm problem that shows up twice a month will slip past them. That is the job of a prescription patch. Second, the apps only know a short list of rhythms. Anything else gets labeled "unclassified." That is not a clean bill of health. UK guidance from NICE still treats the 12-lead hospital ECG as the standard for diagnosis. Consumer devices screen and record. They do not diagnose.

Samsung's Galaxy Watch adds a warning worth knowing. Its blood pressure feature arrived in the US in March 2026 as a wellness feature, not an FDA-cleared measurement. It needs a cuff check every 28 days. Cleared ECG and uncleared extras can ship on the same watch. Know which is which.

If you have symptoms

Palpitations, chest pain, fainting, or trouble breathing are reasons to see a doctor, not to self-monitor. A home ECG recorded during a symptom can truly help your doctor, so bring it if you have one. A clean trace between symptoms proves very little. These devices screen and document. Diagnosis stays with a clinician and a 12-lead.

FAQ

Is the Apple Watch ECG accurate enough to rely on? For AFib screening, yes. Pooled studies put it at 94.8 percent sensitivity and 95 percent specificity. It is still a one-lead snapshot, so a normal result does not rule out other problems.

Do I need a subscription for KardiaMobile? No, not for the basics. The 6L spots normal rhythm, AFib, slow rate, and fast rate without one. Extra readings, like atrial flutter or PVCs, sit behind a paid plan or a higher-tier device.

Which at-home ECG is best after a heart procedure? Ask your heart doctor. The common answer is the KardiaMobile 6L, because clinics can read the full six-lead trace, not just the app's verdict.

This is not medical advice. Home ECG devices screen and record. They do not diagnose. If you have symptoms or a health condition, see a doctor.

Related reading

• Apple Watch ECG: How to Take One and Read the Results
• Apple Watch HRV: What It Means and How to Read It
• What's the Difference Between Heart Rate and Resting Heart Rate?

Sources

1. Shahid et al. Meta-analysis of Apple Watch ECG for atrial fibrillation detection. Journal of the American College of Cardiology, 2025. https://www.jacc.org. Pooled sensitivity 94.8%, specificity 95%.
2. Am J Med. Head-to-head comparison of KardiaMobile 6L versus single-lead smartwatch ECGs in atrial fibrillation patients. 2022. https://www.sciencedirect.com/science/article/abs/pii/S0002870322001430. 99% sensitivity, 97% specificity for the 6L.
3. AliveCor. KardiaMobile 6L product page. Accessed September 11, 2026. https://kardia.com/products/kardiamobile6l. Leads, determinations, and pricing.
4. NICE. Evidence review: KardiaMobile single-lead ECG. https://www.nice.org.uk/guidance/htg606/documents/450. Per-tracing accuracy ranges.
5. The Verge. Samsung Galaxy Watch blood pressure arrives in the US as a wellness feature. March 31, 2026. https://www.theverge.com/tech/903946/samsung-galaxy-watch-blood-pressure-monitoring-us-launch. FDA status and calibration requirement.
6. Withings. BeamO support and feature availability pages. Accessed September 11, 2026. https://support.withings.com. FDA clearance scope and pending AFib algorithm.
7. iRhythm. Zio patch product information. https://www.irhythmtech.com. 14-day continuous monitoring, prescription requirement.